NCT06060769 Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging
| NCT ID | NCT06060769 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fifth Affiliated Hospital, Sun Yat-Sen University |
| Condition | Cirrhosis； Tumor |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2023-09-01 |
| Primary Completion | 2029-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,200 participants in total. It began in 2023-09-01 with a primary completion date of 2029-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Quantitative MRI scanning parameters such as T1 mapping, T2 mapping, T1ρ, and elastography are used, combined with clinical and laboratory indicators, to predict the risk of liver cancer in patients with cirrhosis.
Eligibility Criteria
Inclusion Criteria: * 1\. Aged over 18 years old; 2. Liver function Child-Pugh classification A or B; 3. Patients with chronic liver disease who meet the diagnostic criteria for high-risk groups of liver cancer in the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)"; 4. Equipped with Gd-EOB-DTPA enhanced MRI scan images, including T1 mapping, T2 mapping, T2\* mapping, T1ρ and other sequences; 5. With 5-year follow-up data. Exclusion Criteria: * 1\. Patients who are unable to undergo MRI scanning due to claustrophobia, abnormal renal function, etc.; 2. Patients who have undergone liver surgery in the past; 3. Patients with major diseases such as heart failure and tumors.
Contact & Investigator
Yaqin Zhang, MD, Ph.D
STUDY CHAIR
Fifth Affiliated Hospital, Sun Yat-Sen University
Frequently Asked Questions
Who can join the NCT06060769 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cirrhosis； Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06060769 currently recruiting?
Yes, NCT06060769 is actively recruiting participants. Contact the research team at zhyaqin@mail.sysu.edu.cn for enrollment information.
Where is the NCT06060769 trial being conducted?
This trial is being conducted at Zhuhai, China.
Who is sponsoring the NCT06060769 clinical trial?
NCT06060769 is sponsored by Fifth Affiliated Hospital, Sun Yat-Sen University. The principal investigator is Yaqin Zhang, MD, Ph.D at Fifth Affiliated Hospital, Sun Yat-Sen University. The trial plans to enroll 1,200 participants.